HSCI News

A new therapy for treating Type 1 diabetes

Promising early results show that longstanding Harvard Stem Cell Institute (HSCI) research may have paved the way for a breakthrough treatment of Type 1 diabetes. Utilizing research from the Melton Lab, Vertex Pharmaceuticals has developed VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D).

A new therapy for treating Type 1 diabetes
Beta Cells

View News by topic

Aging ALS Alzheimer's Disease Bioengineering Blood Diseases Cancer Cardiovascular Disease Diabetes Endocrine Disease Eye Diseases Fibrosis Gastrointestinal Disease Genetics/Epigenetics Graft-Versus-Host Disease Hearing Loss Immunology Kidney Disease Liver Disease Lung Disease Multiple Sclerosis

Media Inquiries

If you are a journalist looking for an expert to comment on stem cell research, please contact hsci.harvard.edu

If you want to learn about potential stem cell treatments, we encourage you to explore A Closer Look at Stem Cells, the blog of the International Society for Stem Cell Research (ISSCR)

HSCI on Twitter